<p>Clinigene International, a subsidiary of Biocon, and Pacific Biomarkers Inc (PBI) announce a collaborative agreement to address the specialty biomarker and high end clinical trial laboratory needs of the global pharmaceutical and biotechnology industry, Biocon said in a statement.<br /><br />Commenting on the development Biocon Director of Research Services Peter Bains said: "We are delighted that PBI has selected Clinigene as its partner in India and we look forward to supporting PBI in extending and expanding its specialist service offerings".<br /><br />"This partnership with India provides us access to India, an emerging hub for drug development and contact research," Pacific Biomarkers CEO Ronald Helm said.<br /><br />Clinigene is India-based clinical research organisation while PBI is a Seattle-based firm that provides biomarker and specialty efficacy testing services to the drug development industry.<br />Shares of Biocon were trading at Rs 266.15 in the late afternoon trade on the BSE, up 4.01 per cent from previous close.</p>
<p>Clinigene International, a subsidiary of Biocon, and Pacific Biomarkers Inc (PBI) announce a collaborative agreement to address the specialty biomarker and high end clinical trial laboratory needs of the global pharmaceutical and biotechnology industry, Biocon said in a statement.<br /><br />Commenting on the development Biocon Director of Research Services Peter Bains said: "We are delighted that PBI has selected Clinigene as its partner in India and we look forward to supporting PBI in extending and expanding its specialist service offerings".<br /><br />"This partnership with India provides us access to India, an emerging hub for drug development and contact research," Pacific Biomarkers CEO Ronald Helm said.<br /><br />Clinigene is India-based clinical research organisation while PBI is a Seattle-based firm that provides biomarker and specialty efficacy testing services to the drug development industry.<br />Shares of Biocon were trading at Rs 266.15 in the late afternoon trade on the BSE, up 4.01 per cent from previous close.</p>